ArticleGastro hep advances2025
Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The EuroQol-5D (EQ-5D) is a commonly used measure of health utilities to calculate quality-adjusted life years. For the clinical trials that use Chronic Liver Disease Questionnaire-nonalcoholic fatty liver disease (CLDQ-NAFLD) or Short Form-36 (SF-36), ability to convert the health-related quality of life scores (CLDQ-NAFLD or SF-36) to EQ-5D scores provides a valuable method to estimate health utility. Methods: Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study. We used 2 cross-walk algorithms to estimate EQ-5D scores. The first algorithm used 6 domains of CLDQ-NAFLD in a fractional logistic model to yield EQ-5D estimates. The other algorithm included calculation of SF-6D utility scores from SF-36 items, which were fed into a regression model that estimated EQ-5D scores from SF-6D scores. Results: There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis. The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm. The correlations between the 2 estimated EQ-5D scores were up to +0.74. Similar to the total sample, the differences between the mean EQ-5D estimates using either calculation method did not exceed 0.012 in all studied subgroups (by age, sex, obesity, type 2 diabetes, and fibrosis stage). Conclusion: Both cross-walk algorithms for the calculation of the EQ-5D utility scores in MASH patients were estimable with CLDQ-NAFLD or SF-36 instruments. A high positive correlation was seen between the total score and subgroup estimates using either method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.